Literature DB >> 23031255

Lipid raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration.

Simona Donatello1, Irina S Babina, Lee D Hazelwood, Arnold D K Hill, Ivan R Nabi, Ann M Hopkins.   

Abstract

Cancer cell migration is an early event in metastasis, the main cause of breast cancer-related deaths. Cholesterol-enriched membrane domains called lipid rafts influence the function of many molecules, including the raft-associated protein CD44. We describe a novel mechanism whereby rafts regulate interactions between CD44 and its binding partner ezrin in migrating breast cancer cells. Specifically, in nonmigrating cells, CD44 and ezrin localized to different membranous compartments: CD44 predominantly in rafts, and ezrin in nonraft compartments. After the induction of migration (either nonspecific or CD44-driven), CD44 affiliation with lipid rafts was decreased. This was accompanied by increased coprecipitation of CD44 and active (threonine-phosphorylated) ezrin-radixin-moesin (ERM) proteins in nonraft compartments and increased colocalization of CD44 with the nonraft protein, transferrin receptor. Pharmacological raft disruption using methyl-β-cyclodextrin also increased CD44-ezrin coprecipitation and colocalization, further suggesting that CD44 interacts with ezrin outside rafts during migration. Conversely, promoting CD44 retention inside lipid rafts by pharmacological inhibition of depalmitoylation virtually abolished CD44-ezrin interactions. However, transient single or double knockdown of flotillin-1 or caveolin-1 was not sufficient to increase cell migration over a short time course, suggesting complex crosstalk mechanisms. We propose a new model for CD44-dependent breast cancer cell migration, where CD44 must relocalize outside lipid rafts to drive cell migration. This could have implications for rafts as pharmacological targets to down-regulate cancer cell migration.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23031255      PMCID: PMC3502863          DOI: 10.1016/j.ajpath.2012.08.025

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  59 in total

1.  CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration.

Authors:  L Y Bourguignon; H Zhu; L Shao; Y W Chen
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

Review 2.  The CD44 proteins in embryonic development and in cancer.

Authors:  L Sherman; J Sleeman; P Dall; A Hekele; J Moll; H Ponta; P Herrlich
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

3.  Phosphatidylinositol 4,5-bisphosphate and PIP5-kinase Ialpha are required for invadopodia formation in human breast cancer cells.

Authors:  Hideki Yamaguchi; Shuhei Yoshida; Emi Muroi; Masahiro Kawamura; Zen Kouchi; Yoshikazu Nakamura; Ryuichi Sakai; Kiyoko Fukami
Journal:  Cancer Sci       Date:  2010-03-24       Impact factor: 6.716

4.  Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.

Authors:  Gustavo Ortiz-Ferrón; Rosario Yerbes; Adriana Eramo; Ana I López-Pérez; Ruggero De Maria; Abelardo López-Rivas
Journal:  Cell Res       Date:  2008-06       Impact factor: 25.617

5.  Wound-induced ATP release and EGF receptor activation in epithelial cells.

Authors:  Jia Yin; Keping Xu; Jing Zhang; Ashok Kumar; Fu-Shin X Yu
Journal:  J Cell Sci       Date:  2007-02-06       Impact factor: 5.285

6.  Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast.

Authors:  Alaa Afify; Maaya A McNiel; Jacquelyn Braggin; Helen Bailey; Augusto F Paulino
Journal:  Appl Immunohistochem Mol Morphol       Date:  2008-03

7.  New CD44 splice variants associated with human breast cancers.

Authors:  N Iida; L Y Bourguignon
Journal:  J Cell Physiol       Date:  1995-01       Impact factor: 6.384

8.  ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons.

Authors:  S Tsukita; K Oishi; N Sato; J Sagara; A Kawai; S Tsukita
Journal:  J Cell Biol       Date:  1994-07       Impact factor: 10.539

9.  Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2.

Authors:  S Yonemura; M Hirao; Y Doi; N Takahashi; T Kondo; S Tsukita; S Tsukita
Journal:  J Cell Biol       Date:  1998-02-23       Impact factor: 10.539

10.  Tight junctions are membrane microdomains.

Authors:  A Nusrat; C A Parkos; P Verkade; C S Foley; T W Liang; W Innis-Whitehouse; K K Eastburn; J L Madara
Journal:  J Cell Sci       Date:  2000-05       Impact factor: 5.285

View more
  38 in total

1.  NGX6a is degraded through a proteasome-dependent pathway without ubiquitination mediated by ezrin, a cytoskeleton-membrane linker.

Authors:  Li Wang; Xiaoling Li; Bo Xiang; Ming Zhou; Xiayu Li; Wei Xiong; Man Niu; Pingpin Wei; Zeyou Wang; Heran Wang; Pan Chen; Shourong Shen; Shuping Peng; Guiyuan Li
Journal:  J Biol Chem       Date:  2014-11-05       Impact factor: 5.157

2.  Mechanisms Mediating High-Molecular-Weight Hyaluronan-Induced Antihyperalgesia.

Authors:  Ivan J M Bonet; Dionéia Araldi; Eugen V Khomula; Oliver Bogen; Paul G Green; Jon D Levine
Journal:  J Neurosci       Date:  2020-07-14       Impact factor: 6.167

Review 3.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-11-07       Impact factor: 5.922

4.  MiR-199a inhibits the ability of proliferation and migration by regulating CD44-Ezrin signaling in cutaneous squamous cell carcinoma cells.

Authors:  Shao-Hua Wang; Jian-Da Zhou; Quan-Yong He; Zhao-Qi Yin; Ke Cao; Cheng-Qun Luo
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 5.  Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy.

Authors:  Faustino Mollinedo; Consuelo Gajate
Journal:  J Lipid Res       Date:  2020-01-27       Impact factor: 5.922

6.  A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells.

Authors:  Sarah R Elkin; Nawal Bendris; Carlos R Reis; Yunyun Zhou; Yang Xie; Kenneth E Huffman; John D Minna; Sandra L Schmid
Journal:  Cancer Res       Date:  2015-09-10       Impact factor: 12.701

7.  Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma.

Authors:  Vesselin R Penchev; Yu-Tai Chang; Asma Begum; Theodore Ewachiw; Christian Gocke; Joey Li; Ross H McMillan; Qiuju Wang; Robert Anders; Luigi Marchionni; Anirban Maitra; Aykut Uren; Zeshaan Rasheed; William Matsui
Journal:  Mol Cancer Res       Date:  2019-01-17       Impact factor: 5.852

8.  Interleukin-1β-induced Reduction of CD44 Ser-325 Phosphorylation in Human Epidermal Keratinocytes Promotes CD44 Homomeric Complexes, Binding to Ezrin, and Extended, Monocyte-adhesive Hyaluronan Coats.

Authors:  Tiina Jokela; Sanna Oikari; Piia Takabe; Kirsi Rilla; Riikka Kärnä; Markku Tammi; Raija Tammi
Journal:  J Biol Chem       Date:  2015-03-25       Impact factor: 5.157

9.  Phosphatidylinositol 4,5-bisphosphate clusters the cell adhesion molecule CD44 and assembles a specific CD44-Ezrin heterocomplex, as revealed by small angle neutron scattering.

Authors:  Xiaodong Chen; Jahan Ali Khajeh; Jeong Ho Ju; Yogesh K Gupta; Christopher B Stanley; Changwoo Do; William T Heller; Aneel K Aggarwal; David J E Callaway; Zimei Bu
Journal:  J Biol Chem       Date:  2015-01-08       Impact factor: 5.157

Review 10.  Membrane microparticles: shedding new light into cancer cell communication.

Authors:  Paloma Silva de Souza; Roberta Soares Faccion; Paula Sabbo Bernardo; Raquel Ciuvalschi Maia
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-19       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.